I completed my PhD in Oncology at the Aix-Mareille University, where I worked in the Ginestier, Charafe-Jauffret group, on the regulation of STAT3/Fanconi anemia axis and synthetic lethality in the context of tumor heterogeneity. I started my postdoctoral studies in the Vindigni’s lab focusing on the mechanisms of fork breakage and repair after PARP inhibitor exposure in BRCA1 and BRCA2 mutant context.